Drug intelligence / Profile preview

miR-145 ASO

Development stage
Preclinical
Modality
Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration
Not Specified (antisense Oligonucleotides Are Commonly Administered Intravenously, Subcutaneously, Or Locally In Preclinical Studies[5][7][9]; Route For miR-145 Aso Not Reported In Available References)
01

Overview

**miR-145 ASO** is an experimental antisense oligonucleotide designed to specifically inhibit the activity of microRNA-145 (miR-145), a microRNA known to function as a tumor suppressor and regulator of inflammation, vascular smooth muscle cell proliferation, and other pathways. The ASO binds complementarily to the mature miR-145 sequence, blocking its function and thereby modulating the expression of its downstream target genes. Preclinical studies have investigated miR-145 ASO for its ability to modulate immune responses (for example, in experimental autoimmune encephalomyelitis), tumor growth, and inflammatory responses[3][5][7]. miR-145 itself targets multiple proteins and is involved in the control of numerous oncogenic processes, including cell proliferation, invasion, and apoptosis[1][2]. miR-145 ASO represents a potential RNA-targeted therapeutic approach for diseases where miR-145 activity is pathological or dysregulated[3][5].

Other names
miR-145 antisense oligonucleotidemiR145 antisense oligonucleotidemiR 145 antisense oligonucleotidemiR-145 ASO inhibitormiR145 ASO inhibitormiR 145 ASO inhibitoranti-miR-145 ASOanti-miR145 ASOanti-miR 145 ASOmiR-145-5p ASOmiR145-5p ASOmiR 145-5p ASO

Beyond the preview

Go deeper on miR-145 ASO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-145 ASO.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call